Endo Tools Therapeutics (ETT), a Gosselies, Belgium-based company that develops advanced endoscopic medical devices for gastroenterologists, closed a Series C funding round of €5m ($5.7M).
The round was led by Epimède and existing investors (FPIM-SFPI, Chagral Invest and individuals).
In conjunction with the funding, seasoned medical device expert Denis Gestin joined the board as new chairman, along with Philippe Degeer, co-founder of Epimède.
The company intends to use the funds to collect further evidence on the capabilities of its devices as well as to train new users, to improve recognition of the devices and to further develop the company’s main platform, Endomina.
Led by Alexandre Chau, CEO, Endo Tools Therapeutics develops a portfolio of advanced, minimally invasive medical devices for gastroenterologists. Its platform currently targets flexible endoscopic suturing and tissue apposition, which can be used in a variety of procedures in the digestive tract such as bariatric interventions. Other potential uses include procedures where full thickness tissue apposition is required, e.g. Gastroesophageal Reflux Disease (GERD), Endoscopic Full Thickness Resection (EFTR), diverticulum treatment.
ETT is a spin-off from the Université Libre de Bruxelles. It obtained the CE mark for its devices in 2015. First results of bariatric procedures performed with its tissue apposition devices were published in GIE in 2017 and in Endoscopy in 2018.